Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Read more: A сentury of сhemical warfare: why the global ban matters Swiss becomes first woman to head chemical weapons body Read more: Swiss becomes first woman to head chemical weapons body Bad ...

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Indicator species are living organisms that tell us that something has changed or is going to change in their environment. They can be easily observed, and studying them is considered a cost-effective ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...